Researchers have identified beta-sitosterol from Aloe vera as a potential inhibitor of enzymes linked to Alzheimer’s disease. Using computer simulations, the compound demonstrated strong binding to acetylcholinesterase and butyrylcholinesterase, key players in cognitive decline. The findings, published in Current Pharmaceutical Analysis, suggest a promising avenue for plant-based treatments.
Alzheimer’s disease, a progressive disorder affecting memory and cognition, remains a major challenge in medicine. Scientists are exploring natural sources for new therapies, and a recent study highlights Aloe vera’s potential beyond its common use in skin care.
The research, led by Meriem Khedraoui and published in 2025 in Current Pharmaceutical Analysis, employed in silico methods to evaluate Aloe vera compounds. These computer-based techniques, including molecular docking and dynamics simulations, assessed interactions with acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). These enzymes degrade acetylcholine, a neurotransmitter essential for brain signaling, and their overactivity exacerbates symptoms in Alzheimer’s patients.
Beta-sitosterol emerged as the top candidate, showing binding affinities of -8.6 kcal/mol to AChE and -8.7 kcal/mol to BChE—stronger than other tested compounds like succinic acid. “Our findings suggest that beta-sitosterol, one of the Aloe vera compounds, exhibits significant binding affinities and stability, making it a promising candidate for further drug development,” Khedraoui stated.
Further analysis using ADMET profiles indicated favorable absorption, distribution, metabolism, excretion, and low toxicity for beta-sitosterol and succinic acid. “These results highlight the potential of beta-sitosterol as a dual inhibitor, which could be crucial in managing Alzheimer’s disease,” Khedraoui added. Co-author Samir Chtita noted, “The comprehensive analysis supports the potential of these compounds as safe and effective therapeutic agents.”
Though encouraging, the study relies on simulations and calls for laboratory validation and clinical trials. “Our in silico approach offers a promising direction for the development of novel treatments for Alzheimer’s disease,” Khedraoui concluded. This work underscores the value of plant-derived molecules in addressing neurodegenerative conditions.
